Angelo Martignetti
Azienda USL Toscana Sud Est
Poggibonsi, Italy
Poggibonsi, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.
Journal: Minerva urology and nephrology
Published: June 23, 2026
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 06, 2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Journal: Cancer immunology, immunotherapy : CII
Published: February 05, 2024
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
Journal: Clinical and experimental medicine
Published: July 30, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Journal: Cancer immunology, immunotherapy : CII
Published: May 04, 2023
Urinary volatile Organic compounds in non-alcoholic fatty liver disease (NAFLD), type two diabetes mellitus (T2DM) and NAFLD-T2DM coexistence.
Journal: Metabolomics : Official journal of the Metabolomic Society
Published: May 18, 2022
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Journal: Clinical genitourinary cancer
Published: January 15, 2022
Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 15, 2022
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
Journal: European urology focus
Published: November 26, 2021
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
Journal: Clinical colorectal cancer
Published: March 31, 2021
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Journal: Diagnostics (Basel, Switzerland)
Published: December 22, 2020
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.
Journal: Cancers
Published: October 01, 2019
Last Updated: 09/26/2026